PMV Pharma Reports Strong Clinical Data for Lead Cancer Drug Rezatapopt, Confirms NDA Timeline, and Extends Cash Runway

summarizeSummary

PMV Pharmaceuticals reported Q1 2026 financial results, highlighted strong Phase 2 clinical data for rezatapopt in ovarian cancer, announced its publication in the New England Journal of Medicine, and confirmed its cash runway to Q2 2027.

check_boxKey Events

• Strong Phase 2 Clinical Data

  Rezatapopt showed an Overall Response Rate (ORR) of 44% (32/72 patients) per investigator assessment, increasing to 46% (34/74) post-data cutoff, with a median Duration of Response (DoR) of 8.2 months in platinum-resistant/refractory ovarian cancer patients.

• Prestigious Publication

  Phase 1 results from the PYNNACLE study were published in the New England Journal of Medicine, highlighting rezatapopt's antitumor activity and proof-of-concept for p53 reactivation.

• NDA Submission on Track

  The company anticipates submitting a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.

• Orphan Drug Designation Confirmed

  Rezatapopt was granted Orphan Drug Designation by the FDA for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

auto_awesomeAnalysis

This filing provides a significant update on PMV Pharma's lead oncology candidate, rezatapopt, including positive Phase 2 clinical trial results (44-46% ORR, 8.2 months DoR) for platinum-resistant/refractory ovarian cancer, which is crucial for its registrational pathway. The publication in the New England Journal of Medicine adds substantial scientific validation. Furthermore, the company confirmed a cash runway to Q2 2027, providing financial stability for its ongoing development efforts.